Medical Device and Healthcare Industry Trends — 2026-08-30

Top 5 Industry Headlines

• Samsung Biologics launched a 3 trillion won (approx. $2.1 billion) rights offering to secure funds for acquiring a peptide manufacturer and building a new plant.
• Classys downwardly revised its 2026 revenue guidance amid weak domestic demand and delays in integrating its Brazilian subsidiary.
• FDA released a discussion paper on risk-based regulations for the safety and efficacy of medical devices embedded with Generative AI, kicking off a public comment period.
• Samsung Electronics & Medison are expanding their medical device business diversification by moving beyond diagnostic imaging into strategic partnerships with therapeutic technology companies.
• South Korea's Medical AI Industry continues to struggle with commercial monetization as National Health Insurance reimbursement delays persist despite rapid approvals from the Ministry of Food and Drug Safety (MFDS).

Key Corporate Trends (At least 4 items)

Samsung Biologics

• What happened: Decided on a massive rights offering through shareholder allocation followed by public offering of unsubscribed shares to secure financial resources for long-term growth investments.
• Numbers: Raising 3 trillion KRW ($2.17 billion), Purpose: Acquiring a peptide manufacturer and building new production facilities.
• Implications: This move is interpreted as a strategy to expand its portfolio from existing antibody-drug conjugates (ADCs) into the peptide CDMO sector, catering to the diversified demands of global big pharma. Attention is focused on how this large-scale capital raising will impact investment sentiment across the broader biotech sector.

Classys

• What happened: Downwardly revised its annual financial guidance for 2026.
• Numbers: Maintained a target price of 62,000 KRW (Shinhan Securities), Cause: Domestic economic recession and delays in the integration of its Brazil corporate entity.
• Implications: While concerns over slowing growth in the aesthetic medical device market have materialized, analysts suggest a rebound is likely if key overseas markets (such as Brazil) normalize. In the short term, however, it is expected to act as a valuation burden.

Samsung Electronics & Samsung Medison

• What happened: Seeking to expand business into therapeutic technologies beyond diagnostic imaging, strengthening cooperation with external companies.
• Numbers: Expanding therapeutic technology partnerships, including non-invasive ultrasound cancer treatment devices.
• Implications: Transitioning the medical device business model from hardware sales to "diagnosis-treatment" linked solutions. This is an attempt to differentiate themselves amid intensifying competition with global comprehensive medtech giants like GE HealthCare and Philips.

2 sources

koreabiomed.com

koreabiomed.com

koreabiomed.com

koreabiomed.com

South Korean Medical AI Startup Ecosystem (Context including Lunit, VUNO, etc.)

• What happened: Although medical AI software approvals from the MFDS surged, the resolution of reimbursement issues hindering actual commercialization in hospital settings remains sluggish.
• Numbers: Increasing multi-country approvals in the US, Europe, and South Korea vs. delayed domestic health insurance reimbursement.
• Implications: As the structure of "getting approvals but making no money" persists, domestic startups are staking their survival on overseas expansion (especially the US and Japan) or new business diversification. The speed of the Ministry of Health and Welfare's selective reimbursement system improvement remains the key variable.

MFDS, Policy, and Regulations (At least 3 items)

Revision of Medical Device Approval, Notification, and Review Regulations (Notice No. 2026-6)

• Content: Implementation of partial amendments to regulations related to medical device approval and review procedures.
• Target: All medical device manufacturing and importing companies.
• Implementation Date: January 26, 2026 (Currently in effect).
• Industry Impact: Expected to enhance regulatory clarity, simplify administrative procedures, and shorten time-to-market especially for innovative medical devices.

Revision of Enforcement Decree and Institution Designation Regulations under the Digital Medical Products Act

• Content: Partial amendments regarding institution designation and classification systems under the "Digital Medical Products Act".
• Target: SaMD (Software as a Medical Device), AI medical device developers, and evaluation institutions.
• Implementation Date: 2026 Notice No. 5 (Implemented in the first half of 2026).
• Industry Impact: Enhanced the predictability of approval and clearance for AI-based diagnostic assistance solutions by subdividing classification criteria for digital medical products and specifying the roles of evaluation agencies.

Abolition of Sales Suspension Grace Period for GMP Regular Inspection Violations

• Content: Abolishment of the existing "sales suspension grace period" special exemption upon detecting violations during regular medical device GMP inspections, applying immediate and strict sanctions such as sales suspensions.
• Target: In vitro diagnostic and general medical device manufacturing and importing companies.
• Implementation Date: Announced March 26, 2026 (Strongly enforced).
• Industry Impact: Manufacturers must more strictly verify compliance before the expiration of Good Manufacturing Practice (GMP) validity periods. The risk of market exit upon violation has increased, raising the maintenance costs and administrative burden of quality systems for manufacturers.

Digital Health & AI Medicine (At least 3 items)

• FDA Generative AI Regulatory Framework: The FDA released a risk-based regulatory discussion paper to assess potential risks (hallucinations, data security, etc.) of medical devices containing generative AI and requested industry feedback.
• Criticism of Insufficient Clinical Validation for AI Medical Devices: A recent study (PLOS Digital Health) revealed that out of 1,357 FDA-cleared AI/ML medical devices, very few underwent clinical trials proving actual patient outcomes improvements.
• Cybersecurity Threats in Wearable and AI Diagnostics: With the proliferation of FDA-approved wearable devices like the Samsung Galaxy Ring and AI diagnostic tools, cybersecurity protocols to prevent hacking and data leaks have emerged as a core operational challenge in healthcare settings.

Global Medtech Context

• FDA's Stance on Deregulating AI and Wearables: The FDA issued guidance exempting low-risk wellness features and certain clinical decision support (CDS) tools from medical device oversight. — Implication for Korean industry: Domestic digital health startups may seize opportunities as regulatory barriers in the US market ease.
• Samsung Healthcare's Vertical Integration Strategy: Samsung Electronics is accelerating the establishment of a vertically integrated ecosystem connecting medical imaging equipment (Medison), consumer wearables (Galaxy Watch/Ring), and cloud data platforms. — Implication for Korean industry: Platform-based comprehensive solution capabilities, rather than single-device manufacturing, will be core to future competitiveness.
• Concentration of FDA Approvals for Global Medtech Startups: Medtech startups capturing attention in 2026 are focusing on developing procedure-driven devices with clear FDA approval pathways and commercialization strategies. — Implication for Korean industry: Moving beyond mere ideas to design clinical data and regulatory strategies from the early stages is essential.

Investment, M&A, and IPO Trends

• Samsung Biologics Rights Offering: Conducting a 3 trillion won rights offering, planned to be used for acquiring a peptide manufacturer and CAPEX investment funds.
• Classys Brokerage Report: Shinhan Securities maintained a "Buy" investment opinion and a target price of 62,000 KRW for Classys, pointing to the normalization of its Brazilian subsidiary as a core catalyst.

Today's Insight

Samsung Biologics' massive rights offering suggests that the bio CDMO industry is expanding beyond mere manufacturing into next-generation modalities like peptides. Conversely, Classys' downward guidance revision is the result of market maturity and macroeconomic uncertainty colliding in the aesthetic medical device market, which previously held high growth expectations. The FDA's push to organize generative AI regulations and demand stricter clinical validation serves as another warning to Korean AI medical device companies that "proving clinical value" is a greater survival condition than "approval speed."

This Week's Checkpoints

• Monitor subscription schedule and participation rate for Samsung Biologics' rights offering.
• FDA generative AI medical device regulation feedback deadline and final guidance direction.
• Q3 earnings conference call details for Classys and other aesthetic medical device companies.

Reader Action Items

• Investors: Reexamine potential share dilution after Samsung Biologics' rights offering and the competitive landscape of the peptide CDMO market.
• Developers/Founders: Review the FDA's generative AI regulatory discussion paper and streamline risk assessment processes for their own products.
• Practitioners: Update quality documentation and internal audit systems in preparation for the MFDS's tightening GMP inspection trends.